Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer(2025 Edition)OA
Breast cancer represents a major threat to women's health in China.Its continuously rising incidence contributes to a growing disease burden,thereby creating a critical demand for novel and effective therapeutic strategies.In recent years,poly ADP-ribose polymerase(PARP)inhibitors,as a novel class of anti-tumor drugs targeting the DNA damage repair pathway,have demonstrated remarkable efficacy in treating breast cancer with BRCA1/2 mutations.By selectively inhibiting DNA repair in tumor cells,these agents induce a“synthetic lethality”effect,offering a new option for precision therapy.Currently,PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use.This consensus,based on the latest evidence-based medical data,provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment,aiming to serve as a reference for clinical practice.
Fei Ma;Binghe Xu;China Anti-Cancer Association Committee on Clinical Research of Anticancer Drugs;National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs;Breast Cancer Expert Committee of National Cancer Quality Control Center;Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center
Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China
医药卫生
breast cancerclinical applicationPARP inhibitorssafety managementtargeted therapy
《Cancer Innovation》 2026 (3)
P.9-19,11
Noncommunicable Chronic Diseases-National Science and Technology Major Project,Grant/Award Number:2023ZD0502200National Natural Science Foundation of China,Grant/Award Number:92459304Major Collaborative Innovation Project of the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences,Grant/Award Number:2022-I2M-2-001。
评论